concealed penis
Conditions
Interventions
R:Intravenous 0.9% sodium chloride solution and sacral block with 0.2% ropivacaine(0.5ml/kg)
RHcau:Intravenous 0.9% sodium chloride solution and sacral block with 0.2% ropivacaine and hydromorphone mixture(0.5ml/kg)
RHiv:Intravenous hydromorphone(10ug/kg) and sacral block with 0.2% ropivacaine(0.5ml/kg)
Sponsors
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
Male
Age
3 Years to 10 Years
Inclusion criteria
Inclusion criteria: 1.ASAI-II 2.Age 3-10 years old 3.Elective concealed penis lengthening 4.Voluntarily participate in this trial and sign the informed consent statement 5.Meet the weight criteria in the attached table
Exclusion criteria
Exclusion criteria: 1. A history of allergy to the test drug 2. Presence of coagulation disorders 3. Those with developmental delay or mental retardation 4. Recent upper respiratory tract infection and sacrococcygeal skin infection 5. Combination of sacral canal closure and spinal disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of postoperative analgesia; | — |
Secondary
| Measure | Time frame |
|---|---|
| FLACC Pain Assessment Scale;Duration of postoperative sedation;Pediatric anesthesia emergence delirium;postoperative adverse reaction within 24 hours;Post Hospitalization BehaviorQuestionnaire for Ambulatory Surgery;Adverse effects during induction;Blood pluse;Heart rate; | — |
Countries
China
Contacts
Public ContactHan Lin
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Outcome results
None listed